top of page
Browse by category
Search


First dual GCG/GLP-1ra gains approval from China’s NMPA for chronic weight management
China's National Medical Products Administration (NMPA) has approved Innovent Biologics’ mazdutide, a first-in-class dual glucagon...


First participant dosed GLORY-OSA trial of mazdutide in China
The first participant has been successfully dosed in a Phase 3 clinical trial (GLORY-OSA) of mazdutide, a dual glucagon (GCG) and...


GLORY-1 outcomes shows positive results for mazdutide - a dual glucagon GCG-1/GLP-1 receptor agonist
The results from GLORY-1 - a Phase 3 clinical study of mazdutide - a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor...


Innovent’s DREAMS-1 trial of mazdutide GLP-1R and GCGR dual agonist meets study endpoints
Innovent Biologics’ Phase 3 clinical trial (DREAMS-1) of mazdutide a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor...


Innovent’s GLORY-1 trial assessing mazdutide meets its primary endpoints
Innovent Biologics has announced the key results of the first Phase 3 clinical trial of mazdutide in Chinese adults with overweight or...


Mazdutide superior compared with dulaglutide for glycaemic control, weight loss, blood lipid and pressure
Innovent Biologics’ Phase 3 clinical trial (DREAMS-2) of mazdutide (IBI362) in Chinese subjects with type 2 diabetes (T2D) has met its...


First patient in GLORY-2 study for mazdutide 9mg in Chinese adults with obesity
The first participant has been successfully dosed in Innovent Biologics’ Phase 3 clinical trial (GLORY-2) of higher dose 9mg mazdutide, a...


Journal Watch 20/12/2023
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...


Mazdutide 9mg results in mean percent change in body weight of 15.4% at 24 weeks
Innovent Biologics has revealed its phase 2 clinical study of higher dose (9mg) mazdutide in Chinese adults with obesity achieved the...


Innovent starts Phase 2 Clinical Trial of mazdutide in Chinese adults with obesity
Innovent Biologics has announced that the first participant has been successfully dosed in the higher-dose cohort of a phase 2 clinical...
Browse by tag






bottom of page